Zacks Research Weighs in on AbbVie’s Q1 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Equities researchers at Zacks Research upped their Q1 2026 earnings estimates for AbbVie in a report released on Thursday, March 13th. Zacks Research analyst S. Ganoria now expects that the company will earn $2.88 per share for the quarter, up from their previous forecast of $2.87. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q2 2026 earnings at $3.33 EPS, Q3 2026 earnings at $3.63 EPS, Q4 2026 earnings at $3.80 EPS, FY2026 earnings at $13.64 EPS and FY2027 earnings at $14.89 EPS.

Several other equities analysts also recently commented on the stock. Wells Fargo & Company upped their price objective on shares of AbbVie from $210.00 to $240.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $220.00 price objective on shares of AbbVie in a research note on Tuesday, December 17th. Morgan Stanley increased their price target on shares of AbbVie from $224.00 to $239.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Piper Sandler increased their price target on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Finally, Bank of America increased their price target on shares of AbbVie from $200.00 to $223.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $211.45.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $211.90 on Monday. The company has a market cap of $374.07 billion, a price-to-earnings ratio of 88.29, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The company has a 50-day moving average price of $191.09 and a 200-day moving average price of $188.05. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. AbbVie has a 12 month low of $153.58 and a 12 month high of $218.66.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same quarter in the previous year, the business earned $2.79 EPS.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Lansforsakringar Fondforvaltning AB publ bought a new position in AbbVie in the fourth quarter worth approximately $104,347,000. PKO Investment Management Joint Stock Co bought a new stake in shares of AbbVie during the 4th quarter valued at $2,399,000. Northstar Financial Companies Inc. bought a new stake in shares of AbbVie during the 4th quarter valued at $1,219,000. Centaurus Financial Inc. raised its position in shares of AbbVie by 2.3% during the 4th quarter. Centaurus Financial Inc. now owns 8,507 shares of the company’s stock valued at $1,512,000 after purchasing an additional 188 shares during the period. Finally, Lighthouse Financial LLC bought a new stake in shares of AbbVie during the 4th quarter valued at $700,000. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the transaction, the executive vice president now directly owns 22,381 shares in the company, valued at approximately $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy J. Richmond sold 29,917 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the completion of the transaction, the executive vice president now owns 44,284 shares in the company, valued at $8,985,223.60. The trade was a 40.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,639 shares of company stock worth $11,067,025. 0.25% of the stock is owned by insiders.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.10%. The ex-dividend date is Tuesday, April 15th. AbbVie’s dividend payout ratio is currently 273.33%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.